Go to main content

Press Releases

Explore the archived press releases about AOP Health, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via aop-health@aoporphan.com 

AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)

21. 2. 2019

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®

17. 12. 2018

AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2018

3. 12. 2018

AOP Orphan is the winner of the innovation award MERCUR’18 in the category ”Life Science”

15. 11. 2018

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

12. 10. 2018

AOP Orphan announces progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b

11. 6. 2018